Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia

Muhammad Ishaq; Nasir Ali Afsar; Syeda Urooj Riaz; Muslim Abbas; Muhammad Shariq Mukarram; Khizra Ishaq; Shifa Ishaq; Muhammad Sanowar Ali

doi:10.5455/JMRR.20231226053523

J Med Res Rev. 2024; 2(1): 21-29

doi: 10.5455/JMRR.20231226053523

Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia

Muhammad Ishaq, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, Muhammad Sanowar Ali.

Cited By:2

Abstract
BACKGROUND:
Drug repurposing is an important approach to treat COVID-19 pandemic. Among various drugs that were felt efficacious we had to use the ones that were low cost, efficacious and readily available. Antibacterial drug teicoplanin has shown some promise in this regard. This study evaluates the therapeutic benefits of using teicoplanin in COVID-19 pneumonia patients.
METHODS:
In this case-control study, 39 patients of COVID-19 were included. The controls (n=19) had received azithromycin for seven days while the cases (n=20) received teicoplanin for ten days. The primary outcomes included the limitations on activity due to illness, need for hospitalization, need for supplemental oxygen therapy and/or ventilation by the 14th day of starting treatment. While the secondary outcomes included same parameters recorded on interim basis by the 7th day of starting treatment.

RESULTS:
A total of 39 patients, including 12 females and 27 males diagnosed with COVID-19 were included in this study, who had received antibacterial drugs azithromycin (n=19) or teicoplanin (n=20) as part of the treatment. The teicoplanin group had a consistently lower prevalence of fever on days 7, 10 and 15 (p <0.001, <0.001 and 0.02 respectively). Despite suffering from a severer form of the disease, the teicoplanin group showed a rapid recovery in terms of cough and shortness of breath. Similarly, they had a significantly better recovery from the loss of smell sensation by day 15 (p=0.039).
CONCLUSIONS:
Teicoplanin use is associated with rapid recovery from febrile illness as well as improvement in clinical and biochemical features in moderate-to-severe COVID-19 pneumonia.

Key words: COVID-19, SARS-CoV-2, Pneumonia, Azithromycin, Teicoplanin

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	HTML Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Muhammad Ishaq Articles by Nasir Ali Afsar Articles by Syeda Urooj Riaz Articles by Muslim Abbas Articles by Muhammad Shariq Mukarram Articles by Khizra Ishaq Articles by Shifa Ishaq Articles by Muhammad Sanowar Ali
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. 2024; 2(1): 21-29.

doi:10.5455/JMRR.20231226053523

Web Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. https://www.wisdomgale.com/jmrr/?mno=182674 [Access: June 27, 2026].

doi:10.5455/JMRR.20231226053523

AMA (American Medical Association) Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. 2024; 2(1): 21-29.

doi:10.5455/JMRR.20231226053523

Vancouver/ICMJE Style

Ishaq M, Afsar NA, Riaz SU, Abbas M, Mukarram MS, Ishaq K, Ishaq S, Ali MS. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev. (2024), [cited June 27, 2026]; 2(1): 21-29.

doi:10.5455/JMRR.20231226053523

Harvard Style

Ishaq, M., Afsar, . N. A., Riaz, . S. U., Abbas, . M., Mukarram, . M. S., Ishaq, . K., Ishaq, . S. & Ali, . M. S. (2024) Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. J Med Res Rev, 2 (1), 21-29.

doi:10.5455/JMRR.20231226053523

Turabian Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. 2024. Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. Journal of Medical Research and Reviews, 2 (1), 21-29.

doi:10.5455/JMRR.20231226053523

Chicago Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. "Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia." Journal of Medical Research and Reviews 2 (2024), 21-29.

doi:10.5455/JMRR.20231226053523

MLA (The Modern Language Association) Style

Ishaq, Muhammad, Nasir Ali Afsar, Syeda Urooj Riaz, Muslim Abbas, Muhammad Shariq Mukarram, Khizra Ishaq, Shifa Ishaq, and Muhammad Sanowar Ali. "Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia." Journal of Medical Research and Reviews 2.1 (2024), 21-29. Print.

doi:10.5455/JMRR.20231226053523

APA (American Psychological Association) Style

Ishaq, M., Afsar, . N. A., Riaz, . S. U., Abbas, . M., Mukarram, . M. S., Ishaq, . K., Ishaq, . S. & Ali, . M. S. (2024) Teicoplanin use is associated with rapid clinical improvement in COVID-19 pneumonia. Journal of Medical Research and Reviews, 2 (1), 21-29.

doi:10.5455/JMRR.20231226053523